Qingshi Yongjun raises Series A for brain-computer implants
Hangzhou-based Qingshi Yongjun has raised a Series A of several hundred million yuan from a group led by domestic healthcare and state-backed funds to take invasive brain-computer implants into clinical trials.
Hangzhou Qingshi Yongjun Medical Equipment has raised a Series A round of several hundred million yuan, the company said on 20 November, with a syndicate of Chinese healthcare and state-backed investors.
The investors include Puhua Capital, Shenzhen Capital Group, Green Pine Capital, Dongfang Jiafu, Longtian Fund, Shenzhen High-Tech Investment, Ginkgo Valley Capital and Oufang Angel. The company did not disclose the exact amount, the post-money valuation or the stake sold, describing the round only as "several hundred million yuan".
The proceeds will go into registration clinical trials and medical device registration filings, the expensive stage where a laboratory demonstrator becomes a regulated product. Qingshi Yongjun is developing invasive brain-computer interface devices, a segment that requires neurosurgery, long follow-up and regulator-grade manufacturing rather than the consumer headbands that defined the first wave of the sector.
The round matters for the wider market because brain-computer interfaces sit among the future industries prioritised in China's 15th Five-Year Plan. A syndicate that mixes healthcare specialists, local government guidance money and angel investors shows RMB capital is willing to fund the category through the trial valley, not just at the concept stage.
What next: the trial protocol, ethics and hospital approvals, and whether the company reaches registration before better-capitalised rivals. A later round with a medical device strategic would be the signal to watch.
Original source: Dahe Cube · 21 Nov 2026
